Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC

  • STATUS
    Recruiting
  • End date
    Dec 18, 2025
  • participants needed
    120
  • sponsor
    Ming Zhao
Updated on 2 June 2021

Summary

This is a randomized, controlled, phase 2 study to assess the efficacy and safety of ablation followed by tislelizumab versus ablation alone in patients with early recurrent hepatocellular carcinoma.

Description

Ablation is one of the main treatments for early recurrent HCC, and its immune stimulation is expected to improve the efficacy of anti-PD-1 immune checkpoint inhibitor therapy. Tislelizumab is a new immunotherapy agent with independent intellectual property rights in China, which is highly efficient and safe. It is of great value to combine Tislelizumab with ablation to reduce the risk of recurrence in HCC patients. In this study, early-stage HCC patients with high risk of recurrence would be included and randomly assigned to receive ablation plus Tislelizumab or ablation alone. The tumor recurrence, overall survival and safety would be observed and recorded to analyze whether Tislelizumab can reduce the recurrence rate.

Details
Condition Recurrent Hepatocellular Carcinoma
Treatment ablation, tislelizumab
Clinical Study IdentifierNCT04663035
SponsorMing Zhao
Last Modified on2 June 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Pathological diagnosed HCC
The recurrent lesions should meet the diagnostic and staging criteria of the Barcelona liver cancer clinical system (BCLC) recommended by the American Association of liver Diseases and the European Association of liver Diseases (AASLD/EASL). The specific diagnostic criteria for HCC are as follows
Intrahepatic lesions 1cm, with typical HCC findings in dynamic contrast-enhanced CT or MRI, that is, enhancement in arterial phase or decreased enhancement in portal phase
II. Intrahepatic lesions 1cm without typical imaging findings, the biopsy can
be performed
III. Intrahepatic lesions < 1cm, ultrasound follow-up every 4 months, if the
enlargement exceeds 1cm, then refer to standard I or II
\. If the intrahepatic recurrent lesions are diagnosed by the above criteria
BCLC-0/A stage can be performed as follows
I. BCLC-0: single lesion < 2cm, Child-Pugh A (without ascites), and ECOG-PS 0
II.BCLC-A: single lesion 2cm, Child-Pugh A (without ascites), and ECOG-PS 0
III.BCLC-A stage: 2-3 lesions but all are less than 3cm. Child-Pugh A (without
ascites), and ECOG-PS 0
\. The recurrence time of HCC should be between 3 and 12 months
\. Patients with recurrent HCC lesions should meet the indications of
ablation treatment, as follows
I. Single lesion 5 cm; or. II. 2-3 lesions, all are less than 3cm; and. III
The location of the above lesions should be far away from the dangerous sites
\. Life expectancy 12 months. 7. The laboratory test shall be completed
within 7 days before the screening and the following criteria shall be met: I
Adequate hematologic function
WBC 2.0 x 109/L (stable, off any growth factor within 4 weeks of study drug administration)
Neutrophils 1.5 x 109/L (stable, off any growth factor within 4 weeks of study drug administration)
Platelets 60 x 109/L (transfusion to achieve this level is not permitted)
Hemoglobin 80 g/L (may be transfused to meet this requirement)
II. Adequate hepatic function
Serum Aspartate Aminotransferase (AST) < 8 X ULN
Serum Alanine Aminotransferase (ALT) < 8 X ULN
Serum total bilirubin < 3 mg/dL
Serum albumin 2.8 g/dL
III. Adequate coagulation function
a)Prothrombin time (PT)-international normalized ratio (INR) 2.3 or PT < 6
seconds above control
IV. Adequate renal function
Creatinine Crack >40 mL/min (Cockcroft-Gault formula) a serum creatinine of < 1.5 ULN

Exclusion Criteria

Target lesion
Known fibrolamellar HCC, sarcomatous HCC, or mixed cholangiocarcinoma and HCC
Patients who have undergone a liver transplant or those who are in the waiting list for liver transplantation
With vascular invasion and extrahepatic metastases
General condition
Patients with cardiac pacemaker implantation. 2. Any history of hepatic encephalopathy. 3. Any prior (within 1 year) or current clinically significant ascites as measured by physical examination and that requires active paracentesis for control
Any history of clinically meaningful variceal bleeding within the last 3 months 5. Hepatitis B virus DNA copy number > 500 IU/mL. 6. Hepatitis D infection in subjects with hepatitis B. 7. Prior malignancy active within the previous 5 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, prostate cancer without evidence of PSA progression or carcinoma in situ such as the following: gastric, prostate, cervix, colon, melanoma, or breast for example
Subjects with any active autoimmune disease or history of known or suspected autoimmune disease except for subjects with vitiligo, resolved childhood asthma/atopy, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll
Uncontrolled or clinically significant cardiac disease. 10. Positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
Previous / concomitant therapy
Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti- CD137, or anti-CTLA-4 antibody (or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Prior organ allograft or allogeneic bone marrow transplantation
All toxicities attributed to prior anti-cancer therapy other than neuropathy, alopecia and fatigue must have resolved to Grade 1 (NCI CTCAE version 5.0) or baseline before administration of study drug. Subjects with toxicities attributed to prior anti-cancer therapy which are not expected to resolve and result in long lasting sequelae are permitted to enroll. Neuropathy must have resolved to Grade 2 (NCI CTCAE version 5.0)
Active bacterial or fungal infections requiring systemic treatment within 7 days
Use of other investigational drugs (drugs not marketed for any indication) within 28 days or at least 5 half-lives (whichever is longer) before study drug administration
Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note